Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of Veliparib in Ovarian Cancer
NCT03400306Phase 1Withdrawn
- Sponsor
- AbbVie Inc.
- Start
- Nov 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of veliparib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal carcinoma (PPC) (3 arms), sponsored by AbbVie Inc. Primary endpoints: Maximum observed plasma concentration at 8 days, Time to Maximum Observed Plasma Concentration at 8 days and 4 more. Planned start Nov 2021; status: withdrawn.
02
Drugs
veliparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT03400306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03400306.